Meeting
2017 Gastrointestinal Cancers Symposium
KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.
Authors
Andrew X. Zhu
Massachusetts General Hospital, Boston, MA
Andrew X. Zhu , Jennifer J. Knox , Masatoshi Kudo , Stephen L. Chan , Richard S. Finn , Abby B. Siegel , Junshui Ma , Pat Watson , Ann-Lii Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02702414
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS504)
DOI
10.1200/JCO.2017.35.4_suppl.TPS504
Abstract #
TPS504
Poster Bd #
N22
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
First Author: Richard S. Finn
Poster
2017 Gastrointestinal Cancers Symposium
KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.
First Author: Richard S. Finn
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
First Author: Jaekyung Cheon
Poster
2020 Gastrointestinal Cancers Symposium
Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).
First Author: Masatoshi Kudo